6.79
Emergent Biosolutions Inc stock is traded at $6.79, with a volume of 631.36K.
It is up +0.30% in the last 24 hours and up +20.39% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
See More
Previous Close:
$6.77
Open:
$6.79
24h Volume:
631.36K
Relative Volume:
0.57
Market Cap:
$348.15M
Revenue:
$676.80M
Net Income/Loss:
$-8.60M
P/E Ratio:
-24.00
EPS:
-0.2829
Net Cash Flow:
$135.40M
1W Performance:
-0.15%
1M Performance:
+20.39%
6M Performance:
-17.30%
1Y Performance:
-22.31%
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, TEVA, HLN, ZTS, VTRS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
EBS
Emergent Biosolutions Inc
|
6.79 | 348.15M | 676.80M | -8.60M | 135.40M | -0.2829 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Emergent BioSolutions Inc. (EBS) Investigation: Bronstein, Gewirt - The National Law Review
Precision Trading with Emergent Biosolutions Inc. (EBS) Risk Zones - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc.EBS - prnewswire.com
Emergent BioSolutions Inc (ER4.DU) Analyst insights, Price targets and RecommendationsYahoo Finance - Yahoo Finance Singapore
Emergent BioSolutions stock steady as investors weigh recent fundamentals - AD HOC NEWS
Emergent BioSolutions Inc. (EBS) Stock Analysis: Unpacking A 56.7% Potential Upside - DirectorsTalk Interviews
Emergent BioSolutions stock rises on Q2 beat and guidance - AD HOC NEWS
Emergent BioSolutions restarts Massachusetts manufacturing after $34.5M vaccine deal - bizjournals.com
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility - marketscreener.com
Emergent: The MCM Engine Runs, But Naloxone Is Breaking Down - Seeking Alpha
Emergent BioSolutions | 8-K: Current report - Moomoo
Emergent BioSolutions presents transformation update, Q2 results, $40M restructuring savings and revised FY26 guidance - TradingView
Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.
Emergent Biosolutions Inc (EBS) Fundamental & Financial Data - Stocktwits
Emergent BioSolutions: Tough 2026 Outlook Warrant Rating Downgrade (NYSE:EBS) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutions Inc. (EBS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Emergent Biosolutions Stock Price Forecast. Should You Buy EBS? - StockInvest.us
Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutio - The National Law Review
Emergent BioSolutions repurchases $75 million in senior notes By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioSolutions Inc. (EBS) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioS - The National Law Review
Emergent BioSolutions Repurchases $75 Million of Debt at Discount - citybiz
Emergent BioSolutions faces securities fraud pr... - Pluang
Gaithersburg's Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS - BioBuzz
Emergent BioSolutions repurchases $75 million in senior notes - investing.com
Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes, Reducing Debt to $364.7 Million - Quiver Quantitative
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes - marketscreener.com
A $68 million cash outlay retires $75 million in Emergent bond debt - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Emergent BioSolutions Inc. (EBS) And Encourages Shareholders to Reach Out - ACCESS Newswire
Emergent BioSolutions receives $24 million BARDA contract - grafa.com
2026-09-01 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Shareholders to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse
Emergent BioSolutions Inc. Receives Contract Modification Valued At Approximately USD 24 Million From The Biomedical Advanced Research And Development Authority To Supply CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) - marketscreener.com
Emergent BioSolutions receives $24M anthrax vaccine contract By Investing.com - Investing.com Australia
EBS Looks 11.9% Overvalued on GF Value™ Amid Challenging Growth Outlook - GuruFocus
Emergent BioSolutions receives $24M anthrax vaccine contract - investing.com
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) - The Manila Times
Emergent BioSolutions Awarded $24M CYFENDUS Contract | EBS Stock News - Stock Titan
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray - Bioscience Association Manitoba
EBS Looks 8.4% Overvalued on GF Value™ Amid Challenging Growth O - GuruFocus
Emergent BioSolutions wins Canada contract for overdose spray By Investing.com - Investing.com Nigeria
Emergent BioSolutions wins Canada contract for overdose spray - Investing.com Canada
Emergent BioSolutions Awarded Canadian Government Standing Offer for NARCAN Nasal Spray - Quiver Quantitative
Canadian public agencies can buy NARCAN for three years; the spray lasts four - Stock Titan
2026-08-30 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Investors to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse
Emergent BioSolutions Inc. (EBS) Options Chain - finance.yahoo.com
Emergent Biosolutions Inc (EBS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Emergent BioSolutions Inc. (EBS) And Encourages Stockholders to Reach Out - ACCESS Newswire
Emergent (EBS) Shares: Gains 1.97% to Reach $5.18 in the Current Update; Level Watch: Traders Can Monitor the $4.92-$5.44 Range in the Available RecordMedian Line - careplusvn.com
EBS Reinstated by JP Morgan -- Current Rating Underweight - GuruFocus
2026-08-21 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Stockholders to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse
JPMorgan Chase & Co. Begins Coverage on Emergent Biosolutions (NYSE:EBS) - MarketBeat
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):